Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.
This study investigated why chemotherapy often fails to generate robust anti-tumor immunity and how the endogenous peptide thymosin alpha-1 (Tα-1) might address this gap. The researchers first observed that circulating levels of Tα-1 were reduced after chemotherapy in both cancer patients (across multiple tumor types) and tumor-bearing mice. Mechanistically, the study found that chemotherapy-induced cancer cell death produces apoptotic bodies (ABs) that are poorly immunogenic. Tα-1 was shown to bind to these ABs and interact specifically with AB-associated microRNAs—particularly miR146a-5p—protecting them from degradation by lysosomal RNase A inside dendritic cells (DCs). This protection allowed miR146a-5p to activate Toll-like receptor 7 (TLR7), which in turn licensed DC maturation, migration to tumor-draining lymph nodes, and presentation of tumor antigens to CD8+ T cells. In mouse models, therapeutic Tα-1 supplementation synergized with chemotherapy to suppress established tumors in a TLR7-dependent and miR146a-5p-dependent manner. Limitations include that mechanistic and therapeutic efficacy data are primarily from mouse models, with human data limited to observational measurements of circulating Tα-1 levels.
Why this grade: The core mechanistic and therapeutic findings are derived from mouse tumor models and in vitro DC experiments; human data are observational and limited to measuring circulating Tα-1 levels, without interventional or efficacy endpoints in humans.
Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (ABs) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of co-administered or second-line immunotherapies. Here, we found reduced circulating levels of thymosin alpha-1 (Tα-1), a key endogenous peptide hormone with immunomodulatory activity, after chemotherapy treatment in patients with multiple types of cancer and mice bearing established tumors. Tα-1 bound to tumor ABs and interacted with AB-borne microRNAs, including miR146a-5p, following phagocytosis of ABs into the endolysosomal compartment of dendritic cells (DCs). The interaction with Tα-1 protected miR146a-5p from lysosomal RNase A-mediated degradation, allowing miR146a-5p-mediated activation of Toll-like receptor 7 (TLR7) that licenses DC maturation, migration to tumor-draining lymph nodes, and presentation of tumor antigens to activate tumor-specific CD8+ T cells. Therapeutic Tα-1 supplementation produced strong synergy with chemotherapy to control established tumors in mice with high miR146a-5p expression in a TLR7-dependent manner. These findings establish Tα-1 as a pivotal endogenous microRNA chaperone that unlocks a critical limiting step of DC licensing, empowering robust antitumor immunity after chemotherapy.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.